Article

Six-month clinical results positive for dual-optic IOL

San Diego-First trial results with the Synchrony dual-optic accommodative IOL (Visiogen Inc.) indicate that this first-generation lens is safe and performs well. However, lens power calculations should improve via more IOL implantation and calculation adjustment, according to Gerd Auffarth, MD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.